Get started
EMERGENT BIOSOLUTIONS INCEMERGENT BIOSOLUTIONS INCEMERGENT BIOSOLUTIONS INC

EMERGENT BIOSOLUTIONS INC

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

ER4 chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪230.00 M‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−10.21EUR
Net income (FY)
‪−689.02 M‬EUR
Revenue (FY)
‪950.68 M‬EUR
Shares float
‪50.47 M‬
Beta (1Y)
2.85

About Emergent Biosolutions, Inc.

Sector
Health Technology
CEO
Joseph C. Papa
Headquarters
Gaithersburg
Website
emergentbiosolutions.com
Employees (FY)
‪1.6 K‬
Founded
1998
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ER4 is 4.37 EUR — it has increased by 0.32% in the past 24 hours. Watch EMERGENT BIOSOLUTIONS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange EMERGENT BIOSOLUTIONS INC stocks are traded under the ticker ER4.
ER4 stock has fallen by 15.49% compared to the previous week, the month change is a 136.83% rise, over the last year EMERGENT BIOSOLUTIONS INC has showed a 42.55% decrease.
We've gathered analysts' opinions on EMERGENT BIOSOLUTIONS INC future price: according to them, ER4 price has a max estimate of 4.57 EUR and a min estimate of 4.57 EUR. Watch ER4 chart and read a more detailed EMERGENT BIOSOLUTIONS INC stock forecast: see what analysts think of EMERGENT BIOSOLUTIONS INC and suggest that you do with its stocks.
ER4 reached its all-time high on Feb 15, 2021 with the price of 104.00 EUR, and its all-time low was 1.38 EUR and was reached on Feb 20, 2024. View more price dynamics on ER4 chart.
See other stocks reaching their highest and lowest prices.
ER4 stock is 1.14% volatile and has beta coefficient of 2.85. Track EMERGENT BIOSOLUTIONS INC stock price on the chart and check out the list of the most volatile stocks — is EMERGENT BIOSOLUTIONS INC there?
Today EMERGENT BIOSOLUTIONS INC has the market capitalization of ‪230.00 M‬, it has increased by 105.83% over the last week.
Yes, you can track EMERGENT BIOSOLUTIONS INC financials in yearly and quarterly reports right on TradingView.
EMERGENT BIOSOLUTIONS INC is going to release the next earnings report on Jul 25, 2024. Keep track of upcoming events with our Earnings Calendar.
ER4 earnings for the last quarter are 0.55 EUR per share, whereas the estimation was −0.91 EUR resulting in a 160.20% surprise. The estimated earnings for the next quarter are −0.87 EUR per share. See more details about EMERGENT BIOSOLUTIONS INC earnings.
EMERGENT BIOSOLUTIONS INC revenue for the last quarter amounts to ‪278.41 M‬ EUR despite the estimated figure of ‪204.12 M‬ EUR. In the next quarter revenue is expected to reach ‪175.20 M‬ EUR.
ER4 net income for the last quarter is ‪8.34 M‬ EUR, while the quarter before that showed ‪−44.85 M‬ EUR of net income which accounts for 118.60% change. Track more EMERGENT BIOSOLUTIONS INC financial stats to get the full picture.
No, ER4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 27, 2024, the company has ‪1.60 K‬ employees. See our rating of the largest employees — is EMERGENT BIOSOLUTIONS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EMERGENT BIOSOLUTIONS INC EBITDA is ‪119.28 M‬ EUR, and current EBITDA margin is −4.09%. See more stats in EMERGENT BIOSOLUTIONS INC financial statements.
Like other stocks, ER4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EMERGENT BIOSOLUTIONS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EMERGENT BIOSOLUTIONS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EMERGENT BIOSOLUTIONS INC stock shows the neutral signal. See more of EMERGENT BIOSOLUTIONS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.